The Evolving Role of BTK Inhibitors in Treating Chronic Lymphocytic Leukemia

The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field. 

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients.